Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1157-1162

  Di Minno, Matteo Nicola Dario ^a   Peluso, Rosario ^a   Iervolino, Salvatore ^b   Russolillo, Anna ^a   Lupoli, Roberta ^a   Scarpa, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CLINICAL EVALUATION; DIET THERAPY; DISEASE ACTIVITY SCORE; FEMALE; FOLLOW UP; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MINIMAL DISEASE ACTIVITY; OBESITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; TREATMENT RESPONSE; WEIGHT REDUCTION;

DISEASE ACTIVITY; PSORIATIC ARTHRITIS; TNF-ALPHA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CALORIC RESTRICTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; OBESITY; OVERWEIGHT; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899951948     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202812     Document Type: Article

References (42)

1. Tyrrell PN, Beyene J, Feldman BM, et al. Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2010;30: 1014-26.
2. Di Minno MND, Iervolino S, Lupoli R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherosclerosis. Semin Thromb Hemost 2012;38: 497-505.
3. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72: 211-16.
4. Love TJ, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71: 1273-7.
5. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34: 585-92. (Pubitemid 39643120)
6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11: 327-32.
7. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19: 972-8. (Pubitemid 29177345)
8. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108: 2957-63. (Pubitemid 37553561)
9. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44: 2737-45. (Pubitemid 34016192)
10. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65: 1551-7. (Pubitemid 44799664)
11. Dixon WG, Symmons DP. What effects might anti-TNF-alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF-alpha in cardiovascular pathophysiology. Ann Rheum Dis 2007;66: 1132-6. (Pubitemid 47309726)
12. Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66: 1503-7. (Pubitemid 350032660)
13. Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247: 349-58. (Pubitemid 30180037)
14. Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013;52: 62-7.
15. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006;29: 81-90. (Pubitemid 43780349)
16. Di Minno MN, Peluso R, Iervolino S, et al. Obesity and the prediction of minimal disease activity. A prospective study in Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2013;65: 141-7.
17. Hermsdorff HH, Zulet MÁ, Abete I, et al. Discriminated benefits of a Mediterranean dietary pattern within a hypocaloric diet program on plasma RBP4 concentrations and other inflammatory markers in obese subjects. Endocrine 2009;36: 445-51.
18. Hermsdorff HHM, Zulet MA, Bressan J, et al. Impact of caloric restriction and Mediterranean food-based diets on inflammation accompanying obesity and metabolic syndrome features. Obe Metab 2009;5: 69-77.
19. Nicklas BJ, Ambrosius W, Messier SP, et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 2004;79: 544-51. (Pubitemid 41103895)
20. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54: 2665-73. (Pubitemid 44205029)
21. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3: 55-78.
22. Di Minno MN, Peluso R, Iervolino S, et al. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: A prospective study. Arthritis Res Ther 2012;14:R211.
23. Di Minno MN, Iervolino S, Peluso R, et al. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Artherioscler Thromb Vasc Biol 2011;31: 705-12.
24. Di Minno MN, Tufano A, Guida A, et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res 2011;127: 193-7.
25. Bingham S, Welch A, McTaggart A, et al. Nutritional methods in the European Prospective Investigation of Cancer in Norfolk. Public Health Nutr 2001;4: 847-58. (Pubitemid 32566539)
26. National Collaborating Centre for Primary Care. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London, UK: National Institute for Health and Clinical Excellence, 2006. http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf (accessed 5 Sept 2012).
27. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-818.
28. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28: 88-136. (Pubitemid 46137814)
29. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28: 1462-536.
30. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62: 965-9.
31. Coates LC, Cook R, Lee K, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010;62: 970-6.
32. Iervolino S, Di Minno MN, Peluso R, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers. J Rheumatol 2012;39: 568-73.
33. Gladman DD, Callen JP. Early-onset obesity and risk for psoriatic arthritis. JAMA 2010;304: 787-8.
34. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69: 325-31.
35. Di Minno MND, Iervolino S, Peluso R, et al. TNF-α blockers and carotid intima-media thickness. An emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med 2012;7(Suppl 2):S97-8.
36. Di Minno MND, Iervolino S, Peluso R, et al. Hepatic steatosis and disease activity in subjects with Psoriatic arthritis on TNF-α blockers. J Rheumatol 2012;39: 1042-6.
37. Olivieri I, Mantovani LG, D'Angelo S, et al. Psoriatic arthritis: pharmacoeconomic considerations. Curr Rheumatol Rep 2009;11: 263-9.
38. Peluso R, Cafaro G, Di Minno A, et al. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol Published Online First: 16 April 2013. doi: http://dx.doi.org/10.1007/s10067-013-2252-0
39. Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011;154: 672-9.
40. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70: 905-8.
41. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32: 2016-24. (Pubitemid 41429036)
42. Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl 2):ii49-54. (Pubitemid 40288522)